<PAGE>
- --------------------------------------------------------------------------------
SEC 1746 Potential persons who are to respond to the collection of information
(2-98) contained in this form are not required to respond unless the form
displays a currently valid OMB control number.
- --------------------------------------------------------------------------------
===============================
OMB APPROVAL
===============================
UNITED STATES OMB Number: 3235-0145
SECURITIES AND EXCHANGE COMMISSION ===============================
Washington, D.C. 20549 Expires: November 30, 1999
===============================
Estimated average burden
hours per response. . . 14.9
===============================
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. _6_______)*
ASTREX, INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
Astrex, Inc. Common Stock
- -------------------------------------------------------------------------------
(Title of Class of Securities)
04635-20-8
- -------------------------------------------------------------------------------
(CUSIP Number)
John C. Loring 700 W. Irving Park Rd., Chicago, IL 60613
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
2/24/00
- -------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See ss.240.13d-7 for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
<PAGE>
- -------------------------------------------------------------------------------
CUSIP No. 04635-20-8 Amendment #6 SCHEDULE 13D Page 2 of 3
- -------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE
PERSONS (ENTITIES ONLY).
John C. Loring SS# ###-##-####
Elizabeth J/S Loring SS# ###-##-####
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS) (a) [ ]
(b) [x]
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
N/A
- ------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e)
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
USA/ILLINOIS
- -------------------------------------------------------------------------------
| | SOLE VOTING POWER
NUMBER OF | 7 | John C. Loring 1,646,810 shares
SHARES | | Elizabeth Loring 271,970 shares
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | John & Elizabeth Loring 15,000 shares
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | See 7
|-----|--------------------------------------------------------
| |
| 10 | SHARED DISPOSITIVE POWER
| | See 8
- ---------------|-----|---------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
SEE 7 & 8
- ------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS)
- ------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
34.35%
- ------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN (EP)
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
Schedule 13D
Amendment No. 6 DRAFT
CUSIP 046357-20-8 Page 3 of 3
John C. Loring
This Amendment No. 6 is filed to report a reduction in shares held due to sales
on the open market of 175,000 shares of the Company. There are no other changes
to Schedule 13D, as amended by Amendment No. 5 (the "fifth amendment") to which
this Amendment No. 6 (the "sixth amendment") relates to except as set forth in
this fifth amendment.
Item 4. Purpose of Transaction.
Between February 14 and February 24, 2000 Mr. Loring sold a total of 175,000
shares of the Company on the open market for the purpose of raising funds and
diversifying his portfolio.
Dependant upon the market price and volume of Astrex common stock Mr. Loring
presently contemplates that over the next several months he will sell an
additional, approximately, 200,000 shares of Astrex common stock to diversify
his portfolio and gift to charity an additional, approximately, 125,000 shares
of Astrex common stock. If such presently contemplated additional sales and
gifts do occur over the next several months Mr. Loring together with his family
will still retain approximately 1,608,708 shares of Astrex common stock which
based on the present number of outstanding shares would constitute 28.58 % of
the issue.
The foregoing statements as regard contemplated future actions or inactions
should be understood to represent only statements made in good faith as to Mr.
Loring's contemplated actions or inactions based on certain possibly occurring
conditions and do not represent guarantees that such actions or inactions will
occur or predictions or guarantees that such conditions will occur.
Item 5. Interest in Securities of the Issuer.
(a) In aggregate Mr. And Mrs. Loring own or control 1,933,780 shares of Astrex,
Inc. common stock representing approximately 34.35% of the approximately
5,629,277 outstanding shares.
Signatures.
After reasonable inquiry and the best of my knowledge and belief, I certify that
the information set forth in this statement is true complete and correct.
February 24, 2000
/s/ John C. Loring /s/ Elizabeth J./S. Loring
-------------------- --------------------------
John C. Loring Elizabeth J./S. Loring
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement: provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)
